Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting
Rhea-AI Summary
Benitec Biopharma (NASDAQ: BNTC) announced acceptance of interim clinical results from the ongoing BB-301 Phase 1b/2a first-in-human study for Oculopharyngeal Muscular Dystrophy (OPMD) for an oral presentation at ASGCT 2026.
Data include 12-month follow-up for the first four Cohort 1 completers, a 24-month follow-up for the first Cohort 1 patient, and interim results for the first Cohort 2 patient; presentation is on 05/15/2026 09:15 AM in Boston.
Positive
- 12‑month follow-up reported for first four Cohort 1 completers
- 24‑month follow-up reported for the first Cohort 1 patient
- Acceptance for an oral presentation at ASGCT 2026
- BB‑301 is described as the only clinical‑stage therapeutic in development for dysphagia in OPMD
Negative
- Interim results reflect a very small sample (first four Cohort 1 completers and initial Cohort 2 patient)
- Data are interim and early‑stage, so durability and broader efficacy remain unconfirmed in larger cohorts
News Market Reaction – BNTC
In the Apr 28 session, BNTC declined 3.49%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 11 | Long-term efficacy data | Positive | +2.5% | 24‑month Cohort 1 data showing deepening, durable swallowing improvements. |
| Nov 03 | Interim trial + Fast Track | Positive | -3.1% | Positive interim BB‑301 results and new FDA Fast Track designation. |
| Nov 02 | Clinical update preview | Neutral | -3.1% | Announcement of upcoming Phase 1b/2a Cohort 1 results webcast. |
| Mar 19 | Interim efficacy readout | Positive | +0.9% | Three subjects showing significant swallowing function gains with BB‑301. |
| Feb 14 | Oral abstract acceptance | Positive | +16.0% | Acceptance of late‑breaking oral abstract with positive early BB‑301 data. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Clinical BB-301 updates have generally been positive and often followed by modest single-digit price moves, with occasional sharp gains or selloffs around major conference or designation milestones.
Recent history for Benitec centers on BB-301 clinical milestones. Since Feb 2025, multiple Phase 1b/2a readouts have shown meaningful swallowing improvements and high responder rates in OPMD. A Fast Track designation and durable 24‑month data reinforced the program’s profile. Price reactions have ranged from small moves to a 15.98% spike, indicating that clinically positive updates sometimes translate into strong upside, but can also be met with muted or negative trading.
Key Terms
phase 1b/2a medical
oculopharyngeal muscular dystrophy medical
dysphagia medical
dna-directed rna interference medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Interim clinical results for the BB-301 Phase 1b/2a study include 12-month post-treatment follow-up results for the first four Cohort 1 completers, 24-month post-treatment follow-up results for the first Cohort 1 Patient, and interim clinical results for the first Cohort 2 Patient
- BB-301 is the only clinical-stage therapeutic agent in development for the treatment of dysphagia in patients diagnosed with OPMD
HAYWARD, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announced the acceptance of the interim clinical results from the ongoing BB-301 Phase 1b/2a first-in-human study for Oculopharyngeal Muscular Dystrophy (OPMD) with moderate dysphagia for oral presentation at the 2026 American Society of Gene and Cell Therapy Annual Meeting (ASGCT). Interim clinical results for patients enrolled into Cohort 1 and Cohort 2 will be discussed in an oral presentation at ASGCT, being held in Boston, MA from May 11 – 15, 2026.
Details regarding the BB-301 Oral Presentation are as follows:
Session Name: Long-term safety and durable efficacy in cell and gene therapy
Presentation Date and Time: 05/15/2026, 09:15 AM - 09:30 AM
Location: MCEC Room 257AB (Level 2)
Abstract ID: 448
Presenter: Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer, Benitec Biopharma
About OPMD
There are currently no approved therapies for OPMD, a rare autosomal-dominant degenerative muscle disorder, that impacts nearly 15,000 patients in North America, Europe and Israel. OPMD is caused by a mutation in the poly(A)-binding protein nuclear 1 (PABPN1) gene; PABPN1 is a ubiquitous protein that controls the length of mRNA poly(A) tails, mRNA export from the nucleus and alternative poly(A) site usage. OPMD is a debilitating progressive disease that weakens the pharyngeal muscles, causing severe swallowing difficulties (dysphagia).1 Progressive dysphagia impacts
About BB-301
BB-301 is a novel, modified AAV9 capsid expressing a unique, single bifunctional construct promoting co-expression of both codon-optimized Poly-A Binding Protein Nuclear-1 (PABPN1) and two small inhibitory RNAs (siRNAs) against mutant PABPN1 (the causative gene for OPMD). The two siRNAs are modeled into microRNA backbones to silence expression of faulty mutant PABPN1, while allowing expression of the codon-optimized PABPN1 to replace the mutant with a functional version of the protein. We believe the silence and replace mechanism of BB-301 is uniquely positioned for the treatment of OPMD by halting mutant PABPN1 expression while providing a functional replacement protein. BB-301 has received Orphan Drug Designation from the EMA and Orphan Drug and Fast Track Designations from the FDA.
About Benitec Biopharma Inc.
Benitec Biopharma Inc. (“Benitec” or the “Company”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary “Silence and Replace” DNA-directed RNA interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). A comprehensive overview of the Company can be found on Benitec’s website at www.benitec.com.
Forward Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release include forward-looking statements, including statements regarding Benitec’s plans to develop and commercialize its product candidates, the timing of the completion of pre-clinical and clinical trials, the timing of the availability of data from our clinical trials, the timing and sufficiency of patient enrollment and dosing in clinical trials, the timing of expected regulatory filings and other regulatory steps, and the clinical utility and potential attributes and benefits of ddRNAi and Benitec’s product candidates, and other forward-looking statements.
These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: the success of our plans to develop and potentially commercialize our product candidates; the timing of the completion of preclinical studies and clinical trials; the timing and sufficiency of patient enrollment and dosing in any future clinical trials; the timing of the availability of data from our clinical trials; the timing and outcome of regulatory filings and approvals; the development of novel AAV vectors; our potential future out-licenses and collaborations; the plans of licensees of our technology; the clinical utility and potential attributes and benefits of ddRNAi and our product candidates, including the potential duration of treatment effects and the potential for a “one shot” cure; our intellectual property position and the duration of our patent portfolio; expenses, ongoing losses, future revenue, capital needs and needs for additional financing, and our ability to access additional financing given market conditions and other factors; the length of time over which we expect our cash and cash equivalents to be sufficient to execute on our business plan; unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA and other governmental authorities and other regulatory developments; the Company’s ability to protect and enforce its patents and other intellectual property rights; the Company’s dependence on its relationships with its collaboration partners and other third parties; the efficacy or safety of the Company’s products and the products of the Company’s collaboration partners; the acceptance of the Company’s products and the products of the Company’s collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; greater than expected expenses; expenses relating to litigation or strategic activities; the impact of, and our ability to remediate, the identified material weakness in our internal controls over financial reporting; the impact of local, regional, and national and international economic conditions and events; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission. The Company disclaims any intent or obligation to update these forward-looking statements.
References:
Investor Relations Contact:
Candice Masse
Astr Partners
(978) 879-7273
candice.masse@astrpartners.com
Media Contact:
Audra Friis
Sam Brown Healthcare Communications
(917) 519-9577
audrafriis@sambrown.com
